創美藥業(02289.HK):徐飛獲委任為非執行董事
格隆匯6月1日丨創美藥業(02289.HK)發佈公吿,周濤已向公司遞交辭函,辭任獨立非執行董事職務。辭任已於股東周年大會結束後生效。隨着周先生辭任公司董事,其亦不再擔任董事會審核委員會成員、提名委員會主席、薪酬委員會主席及戰略發展委員會成員。
徐飛已被委任為非執行董事,自股東周年大會之日起生效,並於第三屆董事會任期屆滿為止,任期屆滿後可以膺選連任。公司將與徐先生訂立委任函,徐先生將不會就擔任非執行董事而收取任何薪酬。
中林志傑已向公司遞交辭函,辭任股東代表監事職務。辭任已於股東周年大會結束後生效,但仍擔任公司的其他職位。朱明洪已被委任為股東代表監事,自股東周年大會之日起生效,並於第三屆監事會任期屆滿為止,任期屆滿後可以膺選連任。公司將與朱先生訂立委任函,朱先生將不會就擔任監事而收取任何薪酬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.